ERT, a US headquartered provider of clinical services and customisable medical devices, has appointed Linda Deal to lead its Health Outcomes Research initiatives.
Most recently Deal was the Immunology Patient Reported Outcomes (PRO) lead at Janssen Pharma, a division of Johnson & Johnson. Prior to this, she headed the PRO Centre in Global Health Outcomes Assessment (GHOA) at Wyeth Research, now part of Pfizer. She has also supported health economics and outcomes research for Wyeth, Research Triangle Institute, and Glaxo Welcome.
In the context of health outcomes research ERT’s ePRO solutions are said to offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods.
The ePRO suite comprises an IVR solution (VIAPhone), a digital pen (VIAPen), a handheld device (VIAPad) and an Internet application (VIAWeb).
ERT hires Linda Deal
To head its Health Outcomes Research initiatives
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory
NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach